Boan Biotech (06955.HK): Denosumab Injection 60mg Reaches Licensing Collaboration in Japan

Zhitong Finance APP News, Boan Biotech (06955.HK) announced that the Company has reached a cooperation agreement with a partner regarding the Japanese market rights to its denosumab injection 60mg (BA6101). Under the agreement, the partner will obtain exclusive commercialization rights to the product in Japan, including promotion, sales, and registration filing, and will be fully responsible for its development and market access in Japan; the Company will receive an upfront payment, milestone payments, and sales royalties.